1. Introduction {#sec1}
===============

MicroRNAs (miRNAs) are highly conserved, endogenous non-protein-encoded small molecules with lengths of 21 to 24 nucleotides which can bind to the target sequence of the 3′-untranslated region (3′-UTR) of the target mRNAs, causing degradation or translation inhibition of the target mRNAs at the posttranscriptional level \[[@B1], [@B2]\]. They can negatively regulate gene expression and play an important role in cancer biology, such as cell proliferation, invasion, angiogenesis, and immune evasion \[[@B3], [@B4]\]. In recent years, miRNAs have been considered as potential utility biomarkers for cancer prognosis owing to their robust expression patterns, stability within cancerous samples, and easy assessment by qRT-PCR \[[@B5], [@B6]\].

MicroRNA-497 (miR-497) belongs to the miR-15 superfamily, sharing the same 3′-UTR binding seed sequence AGCAGCA \[[@B7]\]. miR-497 was first reported in human breast cancer \[[@B8]\]. Subsequently, miR-497 downregulation has been demonstrated in various carcinomas, including hepatocellular carcinoma \[[@B9]\], adrenocortical carcinoma \[[@B10]\], and bladder cancer \[[@B11]\], suggesting that miR-497 has a tumor-suppressive role. In addition, many targets of miR-497 have been identified, such as WEE1, IGF-1R, and eIF4E \[[@B12]--[@B14]\]. Recently, some studies indicated that low miR-497 expression was significantly associated with poor prognosis in cancers, containing hepatocellular carcinoma \[[@B15], [@B16]\], renal cancer \[[@B17]\], and neuroblastoma \[[@B12]\]. However, many individual studies have small sample sizes and they have not reached consistent conclusions \[[@B15], [@B18]--[@B20]\]. Thus, the prognostic role of miR-497 in cancers remains unclear.

In this systematic review and meta-analysis, we summarized available data from the published studies to evaluate the role of miR-497 as a prognostic biomarker and to clarify the association between miR-497 expression and long-term survival and early prediction in various carcinomas.

2. Materials and Methods {#sec2}
========================

2.1. Literature Search Strategy {#sec2.1}
-------------------------------

We systematically searched the databases of PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wanfang Data to identify relevant studies up to 15 October 2018. The following search strategies were used to retrieve articles in English or Chinese: "(miR497 OR miR-497 OR microRNA497 OR microRNA-497) AND (neoplasms OR cancer OR carcinoma) AND prognosis." The reference lists of retrieved studies were also examined manually to identify potentially missing relevant studies.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Inclusion criteria are as follows: (1) the full-text article written in English or Chinese, (2) the subjects were patients with any type of carcinoma, (3) miR-497 expression measured in tumor tissue, (4) evaluating the association between the miR-497 expression level and survival outcomes, including overall survival (OS), disease-free survival (DFS), and relapse-free survival (RFS), (5) reporting hazard ratio (HR) with 95% confidence interval (95% CI) or survival curves, and (6) studies based on the same population, with only the latest study included.

Exclusion criteria are as follows: (1) reviews, letters, case reports, and conference reports and (2) lacking key information about survival outcomes.

2.3. Data Extraction {#sec2.3}
--------------------

Two reviewers extracted data independently from eligible studies. The following information was extracted: the first author, publication year, country, ethnicity of patients, number of cases, cancer type, tumor stage, sample type, detection method, follow-up and cut-off values, HR, and the corresponding 95% CI of miR-497 for OS, DFS, and RFS. If obtaining directly is not possible, data were extracted by survival curves and calculated following Tierney et al.\'s method \[[@B21]\]. HR was measured by comparing low expression with high expression (high expression as the reference). HR \> 1 indicates a poor prognosis in the low-expression group.

Disagreements were resolved through comprehensive discussion and examined by a third investigator.

2.4. Quality Assessment {#sec2.4}
-----------------------

The quality of each included study was assessed according to the Newcastle-Ottawa Scale (NOS) criteria for cohort studies \[[@B22]\]. The NOS criteria include three aspects: selection, comparability, and outcome. Nine points is the highest score, and more than six points is high quality \[[@B23], [@B24]\].

The assessments were processed independently by two reviewers and the final score was achieved by consensus.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Statistical analyses were performed using Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) and Stata 14.0 (Stata Corp., College Station, TX, USA), and all tests were 2 tailed. HRs and corresponding 95% CIs extracted directly or by survival curves were used to calculate the pooled HR by the generic inverse variance method. The significance of pooled HR was calculated by the *Z*-test, and *P* \< 0.05 was regarded as statistically significant. Heterogeneity between studies was tested by the *Q* test and *I*^2^ statistics. If *P*~heterogeneity~ \< 0.10 or *I*^2^ \> 50% (heterogeneity existed), the random effects model was applied to calculate pooled HR and meta-regression was further used to explore sources of heterogeneity. If not, the fixed effects model was applied. The subgroup analyses were conducted by ethnicity and cancer type. Sensitivity analyses were performed by omitting each study at a time to assess the consistency and stability of the pooled results. We evaluated potential publication bias by funnel plots and further used Begg\'s test (rank correlation test) \[[@B25]\] and Egger\'s test (weighted linear regression test) \[[@B26]\] to quantitatively evaluate the publication bias. If publication bias existed, the trim and fill method \[[@B27]\] was used to adjust the results.

3. Results {#sec3}
==========

3.1. Summary of the Included Studies {#sec3.1}
------------------------------------

324 studies were initially identified through database searching. 278 studies were further reviewed after duplicates were removed. According to the inclusion and exclusion criteria, 258 studies were excluded after screening titles and abstracts, 20 full-text articles were further assessed for eligibility. One retracted article \[[@B28]\], three articles without sufficient data \[[@B29]--[@B31]\], and one article \[[@B32]\] which brought great clinical heterogeneity were further excluded. Finally, 15 eligible studies were included in the meta-analysis \[[@B12]--[@B20], [@B33]--[@B38]\], including 15 for OS \[[@B12]--[@B20], [@B33]--[@B38]\] and 4 for DFS/RFS \[[@B13], [@B15], [@B33], [@B37]\] ([Figure 1](#fig1){ref-type="fig"}).

The included studies encompassed a total of 1317 patients with OS data and 443 patients with DFS/RFS data from China, Ireland, and Austria, published from 2012 to 2017. The patients could be divided into Asian or Caucasian by their ethnic background. The types of carcinomas included hepatocellular carcinoma (HCC), cervical cancer, neuroblastoma, ovarian cancer, pancreatic cancer, osteosarcoma, breast cancer, gliomas, non-small-cell lung cancer (NSCLC), renal cancer, gastric cancer (GC), diffuse large B-cell lymphoma (DLBCL), colorectal cancer, and Ewing sarcoma. All studies used tissue specimens. Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted in all 15 studies. All of the follow-up time was more than 60 months. The cut-off values were different, most with median or mean. HR and the corresponding 95% CI were obtained directly in 8 studies, and others were extracted and calculated by survival curves.

All studies included in this meta-analysis were cohort studies and assessed based on the NOS. The scores ranged from 6 to 8, and the average score was 7.13. The details of characteristics and the NOS scores were summarized in [Table 1](#tab1){ref-type="table"}.

3.2. miR-497 Expression Level and OS {#sec3.2}
------------------------------------

15 studies evaluated the association of miR-497 expression levels and OS, and the pooled HR was 2.19 (95% CI: 1.84-2.60), which indicated that the lower level of miR-497 expression was associated with shorter overall survival ([Figure 2](#fig2){ref-type="fig"}). Subgroup analyses by ethnicity showed that low miR-497 expression was significantly associated with poor OS in both Asian and Caucasian patients (Asian: HR = 2.10, 95% CI: 1.76-2.51; Caucasian: HR = 4.06, 95% CI: 2.00-8.24). Further subgroup analyses by cancer type also indicated that significant associations were observed in hepatocellular carcinoma and other cancers (HCC: HR = 2.35, 95% CI: 1.58-3.50; other cancers: HR = 2.15, 95% CI: 1.78-2.60). ([Table 2](#tab2){ref-type="table"}).

3.3. miR-497 Expression Level and DFS/RFS {#sec3.3}
-----------------------------------------

Data on DFS/RFS were available in 4 studies, and the pooled result showed no statistical association between miR-497 expression and early predicted survival (HR = 1.17, 95% CI: 0.53-2.57) ([Figure 3](#fig3){ref-type="fig"}). Subgroup analyses by ethnicity also showed negative results in both Asian and Caucasian patients (Asian: HR = 1.42, 95% CI: 0.55-3.67; Caucasian: HR = 0.63, 95% CI: 0.27-1.47). ([Table 2](#tab2){ref-type="table"}).

3.4. Meta-Regression Analysis {#sec3.4}
-----------------------------

To explore the source of heterogeneity of overall survival, we used meta-regression to evaluate the possible covariates including ethnicity, sample size (median 86 as the boundary), cancer type, NOS (mean 7.13 as the boundary), and cut-off. Univariate and multivariate analyses both showed that all the above covariates were not the sources of heterogeneity (*P* \> 0.05). It was indicated that the pooled results were not affected by above covariates ([Table 3](#tab3){ref-type="table"}).

3.5. Sensitivity Analysis and Publication Bias {#sec3.5}
----------------------------------------------

Sensitivity analysis showed that the pooled HRs in OS and DFS/RFS were not significantly influenced by omitting the individual study ([Figure 4](#fig4){ref-type="fig"}).

The shape of the funnel plot did not indicate visual evidence of the asymmetry ([Figure 5](#fig5){ref-type="fig"}). Begg\'s test and Egger\'s test both showed no significant publication bias detected (*P* \> 0.05) ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

Results of this meta-analysis, for the first time, showed that the lower level of miR-497 expression was associated with shorter overall survival but not significantly associated with DFS/RFS in patients with a variety of carcinomas. Subgroup analyses by ethnicity and cancer type showed the consistent results. Sensitivity analyses which were performed by omitting each study at a time did not alter the results. Both analyses indicated that the results of this meta-analysis were stable and reliable.

The main reason for the poor survival of cancer is invasion and metastasis \[[@B39]\]. miR-497 functions mainly as a tumor suppressor, and overexpression of miR-497 suppresses cell proliferation and induces apoptosis in HCC \[[@B15]\] and pancreatic cancer \[[@B34]\] and inhibits migration and invasion in cervical cancer \[[@B13]\] and breast cancer \[[@B18]\]. In addition, miR-497 overexpression was found to initiate G0/G1 cell phase arrest of MCF-7 breast cancer cells \[[@B40]\] and block the G1/S transition of gastric cancer cells \[[@B14]\]. Conversely, miR-497 downregulation contributed to angiogenesis in HCC \[[@B41]\] and ovarian cancer \[[@B42]\]. Knockdown of miR-497 increased cell growth and invasion in NSCLC \[[@B43]\] and induced osteosarcoma cell chemoresistance \[[@B44]\]. Increasing evidences indicated that miR-497 expression might be associated with cancer progression, the current meta-analysis confirmed that it could serve as a long-term prognostic biomarker.

According to the NCI Dictionary of Cancer Terms, DFS and RFS are the same outcomes which are defined as "the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer." Due to the included studies that used DFS or RFS to evaluate early tumor relapse, we combined the two indices to evaluate the early predictive value of miR-497. However, only 4 related studies with a relatively small sample size were included in this meta-analysis, so the result was less reliable to some extent. To confirm whether the miR-497 expression can predict the early tumor relapse or not, more well-designed clinical researches with larger sample sizes should be carried out in the future.

Obvious heterogeneity was discovered when we conducted analysis of the miR-497 expression level and DFS/RFS. In order to find out the origin of heterogeneity, we performed the subgroup and sensitivity analyses. When we omitted the study of Zhang et al. \[[@B15]\], there was no significant heterogeneity observed, so this study was the main source of heterogeneity. Noteworthily, the results of Zhang et al. \[[@B15]\] showed that the cancer-specific survival of HCC was not consistent with the total pooled results. It might suggest that miR-497 could predict the early relapse of HCC, which needed further confirmation.

Although this meta-analysis suggested that miR-497 had clinical utility for the prediction of prognosis in patients with cancers, several issues should be considered about its clinical application. First, it is very important to determine a clear definition of the cut-off value of miR-497 expression. But the lack of abundant miR-497 expression data and the variability in different ethnic populations make it difficult to set a standard cut-off value. Second, several other miRNA prognostic biomarkers of cancers have been reported nowadays, such as miR-210 \[[@B45]\], miR-218 \[[@B46]\], miR-29 \[[@B47]\], and miR-214 \[[@B48]\]. The prediction power of a panel of miRNAs may be stronger than a single miR-497, so using a set of miRNAs or a single miR-497 as predictive factors should be carefully considered. Third, circulating miRNAs represent a class of ideal biomarkers for cancer prognosis, they exhibit higher stability in body fluids and can be extracted and measured noninvasively \[[@B49]\]; so, could we use miR-497 in serum or plasma in place of tissue as prognostic biomarker? However, only one study \[[@B50]\] reported that miR-497 could serve as a potential serum biomarker for the prognosis of osteosarcoma. More relevant studies should be conducted to investigate the association between serum miR-497 expression and cancer prognosis.

This study has several limitations. First, the cut-off value of miR-497 expression was various in original studies, including median, mean, and others, lacking of a golden standard and a clear definition. Second, because survival data of some eligible studies could not be obtained directly by multivariate cox regression, the data extracted from survival curves might not exclude the influence of some potential confounding factors; these calculated HRs and corresponding 95% CIs might also bring several tiny errors. Third, heterogeneity between some studies still existed, although we used several statistical methods to minimize the effect of the heterogeneity, including the random effects model, subgroup analysis, and meta-regression.

In conclusion, the current meta-analysis demonstrated that miR-497 expression was significantly associated with long-term survival, not significantly associated with early prediction. It might suggest that detected miR-497 expression could predict overall survival of cancer patients in the future clinical application. More multicenter prospective clinical researches should be conducted to confirm the association between miR-497 expression and cancer prognosis.
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![(a) Sensitivity analysis for OS. (b) Sensitivity analysis for DFS/RFS. OS: overall survival; DFS: disease-free survival; RFS: relapse-free survival; CI: confidence interval.](DM2019-2491291.004){#fig4}

![(a) Funnel plot for publication bias analysis of OS. (b) Funnel plot for publication bias analysis of DFS/RFS. OS: overall survival; DFS: disease-free survival; RFS: relapse-free survival; HR: hazard ratio.](DM2019-2491291.005){#fig5}

###### 

Characteristics of studies included in the meta-analysis.

  Author                       Year   Country   Ethnicity   Number   Cancer type   Stage               Sample         Method          Follow-up (months)   Cut-off   Survival analysis   Hazard ratio   NOS     
  ---------------------------- ------ --------- ----------- -------- ------------- ------------------- -------------- --------------- -------------------- --------- ------------------- -------------- ------- ---
  Zhang et al. \[[@B15]\]      2016   China     Asian       86       86            HCC                 I-IV (TNM)     Frozen tissue   qRT-PCR              60        Median              OS/DFS         HR/SC   8
  Luo et al. \[[@B13]\]        2013   China     Asian       60       60            Cervical cancer     I-II (FIGO)    Frozen tissue   qRT-PCR              60        Mean (0.44)         OS/DFS         HR/SC   8
  Creevey et al. \[[@B12]\]    2013   Ireland   Caucasian   143      143           Neuroblastoma       1-4 s (INSS)   Frozen tissue   qRT-PCR              60        First Quartile      OS             SC      6
  Wang et al. \[[@B33]\]       2014   China     Asian       96       96            Ovarian cancer      I-IV (TNM)     Frozen tissue   qRT-PCR              60        NR                  OS/RFS         SC      8
  Xu et al. \[[@B34]\]         2014   China     Asian       87       /             Pancreatic cancer   I-IV (TNM)     Frozen tissue   qRT-PCR              87        Score               OS             HR/SC   8
  Liu et al. \[[@B18]\]        2016   China     Asian       240      /             Breast cancer       I-III (TNM)    Frozen tissue   qRT-PCR              80        Median (1.60)       OS             HR/SC   7
  Feng et al. \[[@B35]\]       2016   China     Asian       110      /             Gliomas             I-IV (TNM)     Frozen tissue   qRT-PCR              60        Median (1.73)       OS             HR/SC   7
  Huang et al. \[[@B36]\]      2015   China     Asian       51       /             NSCLC               I-III (TNM)    Frozen tissue   qRT-PCR              60        Median              OS             SC      8
  Zhao et al. \[[@B17]\]       2015   China     Asian       86       /             Renal cancer        T1-T4 (TNM)    Frozen tissue   qRT-PCR              60        Mean                OS             HR/SC   7
  Li et al. \[[@B14]\]         2014   China     Asian       97       /             GC                  I-IV (TNM)     Frozen tissue   qRT-PCR              60        Median              OS             SC      6
  Troppan et al. \[[@B37]\]    2015   Austria   Caucasian   58       58            DLBCL               I-IV (TNM)     Frozen tissue   qRT-PCR              120       Median              OS/DFS         HR/SC   6
  Song et al. \[[@B19]\]       2017   China     Asian       46       /             Osteosarcoma        I-III (TNM)    Frozen tissue   qRT-PCR              72        Mean                OS             SC      7
  Wang et al. \[[@B38]\]^∗^    2012   China     Asian       57       /             Colorectal cancer   I-IV (TNM)     Frozen tissue   qRT-PCR              60        N/T = 2             OS             SC      7
  Zhang \[[@B20]\]^∗^          2016   China     Asian       39       /             Ewing sarcoma       NR             Frozen tissue   qRT-PCR              90        NR                  OS             SC      6
  Xie and Wang \[[@B16]\]^∗^   2017   China     Asian       61       /             HCC                 I-IV (TNM)     Frozen tissue   qRT-PCR              60        Median (0.24)       OS             HR/SC   8

OS: overall survival; DFS: disease-free survival; RFS: relapse-free survival; HCC: hepatocellular carcinoma; NSCLC: non-small-cell lung cancer; GC: gastric cancer; DLBCL: diffuse large B-cell lymphoma; TNM: tumor node metastasis; FIGO: International Federation of Gynaecology and Obstetrics staging criteria; INSS: International neuroblastoma staging system; NR: not reported; qRT-PCR: quantitative real-time PCR; HR: hazard ratio; SC: survival curve; NOS: Newcastle-Ottawa Scale. ^∗^Written in Chinese.

###### 

Main results of pooled HRs in the meta-analysis.

  Comparisons       Heterogeneity test   Pooled HR (95% CI)   Hypothesis test   No. of studies                       
  ----------------- -------------------- -------------------- ----------------- ------------------- ------ --------- ----
  OS                                                                                                                 
   Total            13.71                0.47                 0                 2.19 (1.84, 2.60)   8.89   \<0.001   15
   Ethnicity                                                                                                         
    Asian           8.94                 0.71                 0                 2.10 (1.76, 2.51)   8.19   \<0.001   13
    Caucasian       1.62                 0.20                 38                4.06 (2.00, 8.24)   3.89   \<0.001   2
   Cancer type                                                                                                       
    HCC             0.25                 0.62                 0                 2.35 (1.58, 3.50)   4.21   \<0.001   2
    Other cancers   13.30                0.35                 10                2.15 (1.78, 2.60)   7.84   \<0.001   13
  DFS/RFS                                                                                                            
   Total            12.92                0.005                77                1.17 (0.53, 2.57)   0.39   0.69      4
   Ethnicity                                                                                                         
    Asian           9.99                 0.007                80                1.42 (0.55, 3.67)   0.73   0.47      3
    Caucasian       ---                  ---                  ---               0.63 (0.27, 1.47)   1.07   0.29      1

OS: overall survival; DFS: disease-free survival; RFS: relapse-free survival; HCC: hepatocellular carcinoma; HR: hazard ratio; CI: confidence interval.

###### 

The results of meta-regression analysis of OS.

  Covariates    Univariate analysis   Multivariate analysis                                      
  ------------- --------------------- ----------------------- ------- ------ ----------- ------- -------
  Ethnicity     1.93                  0.87-4.32               0.100   1.70   0.70-4.11   0.208   0.617
  Sample size   1.19                  0.81-1.74               0.352   1.01   0.62-1.63   0.981   1.000
  Cancer type   1.09                  0.67-1.80               0.703   1.43   0.72-2.84   0.272   0.725
  NOS           0.77                  0.53-1.13               0.167   0.74   0.43-1.30   0.259   0.705
  Cut-off       0.99                  0.67-1.46               0.955   0.91   0.56-1.46   0.658   0.984

Adjusted *P* was calculated by the Monte Carlo permutation test for meta-regression. CI: confidence interval; NOS: Newcastle-Ottawa Scale; OS: overall survival.

###### 

Publication bias of miR-497 for Begg\'s test and Egger\'s test.

  Comparisons   Begg\'s test   Egger\'s test                   
  ------------- -------------- --------------- ------- ------- --------------------
  OS            0.20           0.843           0.02    0.983   -1.398477-1.427367
  DFS/RFS       -0.34          1.000           -0.33   0.775   -30.04166-25.80952

OS: overall survival; DFS: disease-free survival; RFS: relapse-free survival; CI: confidence interval.
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